China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ Biosciences Inc., announced the establishment of a refined mRNA process platform. The collaboration offers comprehensive services ranging from gene synthesis, efficient in vitro transcription template preparation, plasmid linearization, IVT mRNA synthesis, purification, and quality inspection, to LNP packaging. No financial details were disclosed.
Platform and Services
Yiming Cell, a gene and cell therapy contract development and manufacturing organization (CDMO) founded in Beijing in 2015, has established platforms for plasmid preparation, viral packaging, cell culture, cell library, process development, and more. WZ Bio provides molecular biology services such as molecular cloning, gene mutation, gene knockdown, and CRISPR/Cas9 gene editing. Together, the companies aim to enhance the efficiency and quality of mRNA-based therapies through this integrated platform.
Future Outlook
With the establishment of this mRNA process platform, Yiming and WZ Biosciences are poised to advance the development and production of innovative gene therapies, leveraging their combined expertise to address significant unmet needs in the field of biotechnology.-Fineline Info & Tech
